Related references
Note: Only part of the references are listed.In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations
Francesco Saladini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis
Chloe Orkin et al.
CLINICAL INFECTIOUS DISEASES (2020)
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
Jean-Michel Molina et al.
LANCET HIV (2020)
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
Cathia Soulie et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations
Carlos Guerrero-Beltran et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
HIV drug resistance profile in South Africa: Findings and implications from the 2017 national HIV household survey
Sizulu Moyo et al.
PLOS ONE (2020)
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
Chloe Orkin et al.
CLINICAL INFECTIOUS DISEASES (2019)
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors
Gaetana Sterrantino et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
Margaret Johnson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
Willem D. F. Venter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
Alexander Wong et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients
Cathia Soulie et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
Andrew N. Phillips et al.
LANCET HIV (2019)
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
Jean-Michel Molina et al.
LANCET HIV (2018)
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa
K. Steegen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Cutting the cost of South African antiretroviral therapy using newer, safer drugs
W. D. F. Venter et al.
SAMJ SOUTH AFRICAN MEDICAL JOURNAL (2017)
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations
Meizhen Feng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways
Meizhen Feng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor
Ming-Tain Lai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy
Ravindra K. Gupta et al.
CLINICAL INFECTIOUS DISEASES (2014)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings
Zhiyong Zhou et al.
PLOS ONE (2011)
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors
B Brenner et al.
AIDS (2003)
Share Paper
